Abstract
The purpose of this study was to assess the serum antibody responses to both the hemagglutinin and the neuraminidase antigens of inactivated influenza vaccine in 45 elderly and 28 younger adults. After vaccination, antihemagglutinin antibody levels increased significantly and mean fold increases ranged from 2.8 to 22.0. Seroprotection rates were between 42.2 and 91.1% 1 month after vaccination and 15.6 and 84.4% 5 months afterward. Seroresponse rates ranged from 42.2 to 91.1% 1 month after vaccination and 15.6 to 82.2% 5 months afterward. After vaccination antineuraminidase antibody levels increased significantly and mean fold increases ranged from 3.6 to 12.3. Significantly higher antibody responses to both hemagglutinin and neuraminidase were observed for antigen A(H3N2) than for antigens A(H1N1) and B. In most instances there were no statistically significant differences between the elderly and the control subjects. Influenza vaccine was immunogenic in the institutionalized elderly, who developed good antibody responses to influenza hemagglutinin and neuraminidase antigens.
Similar content being viewed by others
References
Centers for Disease Control and Prevention: Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 51:RR-3, 2002
Sprenger MJW, Mulder PGH, Beyer WEP, van Strik R, Masurel N: Impact of influenza on mortality in relation to age and underlying disease, 1967–1989. Int J Epidemiol 22:334-340, 1993
Perrotta DM, Decker M, Glezen WP: Acute respiratory disease hospitalizations as a measure of impact of epidemic influenza. Am J Epidemiol 122:468-476, 1985
Strassburg MA, Greenland S, Sorvillo FJ, Lieb LE, Habel LA: Influenza in the elderly: Report of an outbreak and a review of vaccine effectiveness reports. Vaccine 4:38-44, 1986
Meiklejohn G, Hall H: Unusual outbreak of influenza A in a Wyoming nursing home. J Am Geriatr Soc 35:742-46, 1987
Goodman RA, Orenstein WA, Munro TF, Smith SC, Sikes RK: Impact of influenza A in a nursing home. JAMA 247:1451-1453, 1982
Gravenstein S, Miller BA, Drinka P: Prevention and control of influenza A outbreaks in long-term care facilities. Infect Control Hosp Epidemiol 13(1):49-54, 1992
Gomolin IH, Leib HB, Arden NH, Sherman FT: Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management. J Am Geriatr Soc 43(1):71-74, 1995
Zimmerman RK: Prevention of influenza by expanded ages for routine vaccination. J Fam Pract 49:15-21, 2000
Palache AM: Influenza vaccine: A reappraisal of their use. Drugs 54:841-856, 1997
Patriarca PA, Weber JA, Parker RA, Hall WN, Kendal AP, Bregman DJ, Schonberger LB: Efficacy of influenza vaccine in nursing homes: Reduction in illness and complications during an influenza A(H3N2) epidemic. JAMA 253:1136-1139, 1985
Fedson DS: Evaluating the impact of influenza vaccination. A North American perspective. PharmacoEconomics 9 (Suppl 3):54-61, 1996
Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA: The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123:518-527, 1995
Powers DC: Influenza vaccination strategies for the elderly. Aging Immunol Infect Dis 5(1):47-54, 1994
WHO Collaborating Centers for Reference and Research on Influenza: Concepts and Procedures for Laboratory-Based Influenza Surveillance. U.S. Department of Health and Human Services, Public Health Service, Centers for Diseases Control, Atlanta, Georgia, July 1982
Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG: Influenza virus neuraminidase and neuraminidase inhibition test procedures. Bull WHO 48:199-202, 1973
Douglas AR: Assay of neuraminidase (NA) activity and neuraminidase inhibition test. Report of the WHO International Collaborative Center for Reference and Research on the Influenza Virus at Mill Hill. London: National Institute for Medical Research, 1993
Brydak LB, Machaℓa M: Humoral immune response to influenza vaccination in patients from high-risk groups. Drugs 60:35-53, 2000
Nicholson KG. Socioeconomics of influenza and influenza vaccination in Europe. PharmacoEconomics 9:75-78, 1996
Morgan R, King D, Turnbull CJ: Influenza vaccination: Do the aged reap the benefit? Postgrad Med J 71:22-23, 1995
Ambrosch F, Fedson DS: Influenza vaccination in 29 countries. PharmacoEconomics 16 (Suppl 1):47-54, 1999
Brydak LB: Diagnostyka i profilaktyka grypy niezbedne w praktyce lekarza rodzinnego [Diagnostics and prophylaxis of influenza necessary in a family physician's practice]. Standardy Medyczne 12:16-29, 2001 (in Polish)
Glathe H, Bigl S, Grosche A: Comparison of humoral immune responses to trivalent influenza split vaccine in young, middle-aged and elderly people. Vaccine 11:702-705, 1993
Beyer WEP, Palache AM, Baljet M, Masurel N: Antibody induction by influenza vaccines in the elderly: A review of the literature. Vaccine 7:385-394, 1989
Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM: Immune response to influenza vaccination in a large healthy elderly population. Vaccine 17:82-94, 1999
Govaert TME, Sprenger MJW, Dinant GJ, Aretz K, Masurel N, Knottnerus JA: Immune response to influenza vaccination in elderly people. A randomized double blind placebo controlled trial. Vaccine 12:1185-1189, 1994
Remarque EJ, de Bruijn IA, Boersma WJA, Masurel N, Ligthart GJ: Altered antibody response to influenza (H1N1) vaccine in healthy elderly people as determined by HI, ELISA, and neutralisation assay. J Med Virol 55:82-87, 1998
Committee for Proprietary Medicinal Products (CPMP): Note for guidance on harmonisation of requirements for influenza vaccines (revision). CPMP/BWP/214/96, March 12, 1997
Commission of the European Communities. The Rules Governing Medicinal Products in the European Community. Volume III, Addendum No. 2, Guidelines on the quality, safety, and efficacy of medicinal products for human use 93–99, 1992
Van Hoecke Ch, Prikazsky V, ütö I., Menschikowski C: Immunogenicity of an inactivated split influenza vaccine in institutionalized elderly patients. Gerontology 42:190-198, 1996
Brydak LB: Influenza and Its Prophylaxis. Springer PWN, Warsaw, 1998
Ada GL, Jones PD: The immune response to influenza infection. Curr Topics Microbiol Immunol 128:1-54, 1986
Johansson BE, Moran TM, Kilbourne ED: Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci USA 84: 6869-6873, 1987
Kilbourne ED: Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J Infect Dis 134:384-394, 1976
Kilbourne ED, Christenson U, Sande M: Antibody response in man to influenza virus neuraminidase following influenza. J Virol 2:761-762, 1968
Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Wyand CM: Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 75(24):12182-12187, 2001
Hurwitz ES, Haber M, Chang A, Shope T, Teo ST, Giesick JS, Ginsberg MM, Cox NJ: Studies of the 1996–1997 inactivated influenza vaccine among children attending day care: Immunologic response, protection against infection, and clinical effectiveness. J Infect Dis 182:1218-1221, 2000
Iorio AM, Zei T, Neri M, Alatri A: Possible correlation between low antigenic drift of A(H1N1) influenza viruses and induction of HI antibodies. Eur J Epidemiol 12(6):589-594, 1996
Wright PF, Thomson J, Karzon DT: Differing virulence of H1N1 and H3N2 influenza strains. Am J Epidemiol 112:814-819, 1980
Monto AS, Koopman JS, Longini IM: The Tecumseh study of illness. XIII. Influenza infection and disease, 1976–1981. Am J Epidemiol 121:811-822, 1985
Brydak LB, Guzy J, Starzyk J, Machała M, Góźdź S: Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 9:65-68, 2000
Rokicka-Milewska R, Brydak LB, Machała M, Klukowska A: Antibody response to influenza vaccine in children with severe and mild hemophila. Int J Pediatr Hematol/Oncol 7:21-27, 2000
Brydak LB, Rajkowski T, Machała M, Wêglarska J, Sieniawska M: Humoral antibody response following influenza vaccination in patients with nephrotic syndrome. Antiinfect Drugs Chemother 16:151-155, 1998
Zei T, Neri M, Iorio AM: Immunogenicity of trivalent subunit and split influenza vaccines (1989–90 winter season) in volunteers of different groups of age. Vaccine 9:613-617, 1991
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Brydak, L.B., Machała, M., Myśliwska, J. et al. Immune Response to Influenza Vaccination in an Elderly Population. J Clin Immunol 23, 214–222 (2003). https://doi.org/10.1023/A:1023314029788
Issue Date:
DOI: https://doi.org/10.1023/A:1023314029788